# Hemab Therapeutics Holdings, Inc. (COAG)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $25.55 (-5.37%)

> Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for rare bleeding and thrombotic disorders. The company pioneers preventative treatments and functional cures targeting conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease, where current options often fall short in providing effective prophylaxis or long-term management. Hemab's targeted therapies leverage advances in biology and drug modalities to address blood coagulation challenges, aiming to reduce lifelong disease burdens for patients. Operating within the pharmaceuticals and biotech sector, it builds a franchise around select coagulation disorders by uniting expertise in clotting science, patient care, and drug development. Founded in 2020 and headquartered in Cambridge, Massachusetts, Hemab Therapeutics Holdings, Inc. plays a key role in advancing novel solutions for underserved areas of hematology, contributing to improved disease management in rare bleeding disorders.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/COAG)